Lexaria Bioscience Corp. (LEXX) News
Track canonical SquawkNews coverage tagged to LEXX, Lexaria Bioscience Corp.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Lexaria Bioscience raises $7.9M and extends cash runway to 2027
Lexaria Bioscience says it secured $7.9M via an Australian tax refund and institutional financing priced at $12.92/share, extending cash runway through 2027 with no plans for additional 2026 financings.
EQUITY | Sep 17, 2026, 01:11 PM UTC
M
Lexaria closes warrant exercise for about $5.9 million in gross proceeds
Lexaria Bioscience Corp. closed its previously announced exercise of outstanding warrants, raising approximately $5.9 million in gross proceeds. The company says the warrants covered an aggregate of 453…
EQUITY | Sep 09, 2026, 08:16 PM UTC
L
Lexaria Bioscience raises about $5.9 million via warrant exercise
Lexaria Bioscience secured about $5.9 million gross proceeds after holders exercised 453,969 existing warrants at $12.92 per share under inducement offer letters. The company will issue new unregistered Series A and Seri
EQUITY | Sep 09, 2026, 02:14 PM UTC
L
Lexaria enters definitive agreements for immediate warrant exercises
Lexaria Bioscience said it entered definitive agreements for the immediate exercise of certain outstanding warrants, targeting approximately $5.9 million in gross proceeds.
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Lexaria to present at H.C. Wainwright 28th Global Investment Conference
Lexaria Bioscience Corp. (NASDAQ:LEXX) said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 04, 2026, 01:20 PM UTC
L
Lexaria Bioscience gets AUD 3.67 million R&D tax credit
Lexaria Bioscience received an AUD 3,666,611.98 Australian R&D tax credit, or USD 2.6 million, tied to its GLP-1 clinical study.
REGULATION | Sep 01, 2026, 01:24 PM UTC
L
Lexaria receives USD million Australian tax rebate cash payment
Lexaria Bioscience Corp. says it has received a cash tax rebate payment related to its 2025 Australian human study results.
EQUITY | Sep 01, 2026, 01:15 PM UTC
M
US Stocks Announce Reverse Splits
Multiple US stocks undergo reverse splits
EQUITY | Aug 03, 2026, 09:05 AM UTC
L
US Stocks Undergo Reverse Splits
Multiple US stocks undergo reverse splits
EQUITY | Aug 02, 2026, 12:49 PM UTC
M
LEXX: Begins Dosing
Lexaria's human study GLP-1-H26-7 has begun dosing on schedule
EQUITY | Jun 25, 2026, 01:10 PM UTC
L
LEXX: Animal Study Begins
Lexaria's animal study GLP-1-A26-1 has begun dosing on schedule
EQUITY | Jun 23, 2026, 01:26 PM UTC